Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial

Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis

Author:Arnold, Douglas L.   Freeman, Leorah   Hartung, Hans-Peter   Montalbán, Xavier   Cohen, Jeffrey A.   Bar-Or, Amit   Steinman, Lawrence   DeLuca, John   Cheng, Chun-Yen   Riolo, Jon V.   Silva, Diego   Pachai, Chahin   Cree, Bruce A. C.   

Session Name:P5: MS Prognosis/Epidemiology  

Topic:MS and Inflammatory Disease  

Program Number:P5.010  

Author Institution:NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montréal, QC, Canada  Dell Medical School, The University of Texas at Austin, Austin, Texas, Austin, TX  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, Newark, NJ  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  

Continued Validation of the RBD Symptom Severity Scale (RBDSSS) in Participants of the North American Prodromal Synucleinopathy (NAPS) Consortium

Author:Busicescu, Andrea   Choudhury, Parichita   Lee-Iannotti, Joyce   Rangan, Pooja   Fantini, Maria Livia   Shprecher, David   Lim, Miranda   Elliott, John   Avidan, Alon   Huddleston, Daniel   Bliwise, Donald   Howell, Michael   Schenck, Carlos   Criswell, Susan   Xiong, Chengjie   McLeland, Jennifer   During, Emmanuel   Mignot, Emmanuel   Pelletier, Amelie   Gagnon, Jean-Francois   Forsberg, Leah   Fields, Julie   St. Louis, Erik   Videnovic, Aleksandar   Ju, Yo-El   Boeve, Bradley   Postuma, Ronald   

Session Name:P6: Sleep: REM Behavior Disorder  

Topic:Sleep  

Program Number:P6.004  

Author Institution:University of Arizona College of Medicine - Phoenix, Phoenix, AZ  Banner Sun Health Research Institute, Sun City, AZ  Banner University Medical Center, Phoenix, AZ  Banner University Medical Center , Phoenix, AZ  Le Centre Hospitalier Universitaire, Clermont-Ferrand, France  Oregon Health & Science University, Portland, OR  Ohio Health, Columbus, OH  David Geffen School of Medicine at UCLA, Los Angeles, CA  Emory University, Atlanta, GA  University of minnesota, Minneapolis, MN  Minnesota Regional Sleep Disorders Center, Minneapolis, MN  Washington University, Saint Louis, MO  Washington University, St. Louis, MO  Washington University School of Medicine, St. Louis, MO  Stanford, San Francisco, CA  Stanford University, Palo Alto, CA  Montreal General Hospital, Montreal, QC, Canada  Centre D'etude Du Sommeil, Montreal, QC, Canada  Mayo Clinic, Rochester, MN  MGH Neurological Clinical Research Institute, Boston, MA